Reform Priorities for the Industry
Medicines Australia has produced factsheets on the recommendations from our submission to the House of Representatives inquiry into approval processes for new drugs and novel medical technologies.
Medicines Matter. An investment for a healthier tomorrow
Medicines are integral to healthcare delivery and play a vital role in helping Australians live longer and healthier lives; in the workplace, out of hospitals and positively contributing to the community and economy.
Every innovative medicine made available in Australia has the potential to generate a significant return on investment – to the patient, the community, the economy and the government.
Click here to view our full campaign materials.
2019 Federal Election
In the lead up to the Federal Election, Medicines Australia wrote to the major political parties; Liberal/National Coalition, Australian Labor Party and Australian Greens Party, seeking specific commitments to our sector and outlining our key elections asks.
These election asks focused on five areas: PBS listing processes, including special pricing arrangements; Strategic Agreements; National Medicines Policy; Clinical Trials harmonisation; Industry incentives (R&D / intellectual property).
Over recent days Medicines Australia has received response letters from each party formally affirming their commitments to the sector.
As a result of our strong engagement and effective advocacy efforts, supported by our members, all the major parties have made significant, strong commitments to the industry.
Of particular note is bipartisan commitment to improving PBS processes and time to listing; preservation of SPAs; a review of the National Medicines Policy; development of a proposal for Clinical trial harmonisation within 12 months of forming government and ongoing support for strategic agreements with the industry.
The ALP have also agreed to seek an accounting solution to the supply chain reform and have promised no detrimental impact to the supply chain and our members.